These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38552897)

  • 21. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
    Aboudola S; Kotloff KL; Kyne L; Warny M; Kelly EC; Sougioultzis S; Giannasca PJ; Monath TP; Kelly CP
    Infect Immun; 2003 Mar; 71(3):1608-10. PubMed ID: 12595488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.
    Haddad NS; Nozick S; Kim G; Ohanian S; Kraft CS; Rebolledo PA; Wang Y; Wu H; Bressler A; Le SNT; Kuruvilla M; Runnstrom MC; Ramonell RP; Cannon LE; Lee FE; Daiss JL
    J Clin Microbiol; 2022 Mar; 60(3):e0220121. PubMed ID: 35107301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
    Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of the adaptive immune response to SlpA in Clostridium difficile infection.
    Mizrahi A; Bruxelle JF; Péchiné S; Le Monnier A
    Anaerobe; 2018 Dec; 54():164-168. PubMed ID: 30290246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.
    Norman KM; Lang GA; Shadid TM; Honold ST; Reel JM; Cox MA; Ballard JD; Lang ML
    Cell Rep; 2024 May; 43(5):114245. PubMed ID: 38761377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
    Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
    Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
    J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of toxemia in patients with Clostridium difficile infection.
    Yu H; Chen K; Wu J; Yang Z; Shi L; Barlow LL; Aronoff DM; Garey KW; Savidge TC; von Rosenvinge EC; Kelly CP; Feng H
    PLoS One; 2015; 10(4):e0124235. PubMed ID: 25885671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equine hyperimmune serum protects mice against Clostridium difficile spore challenge.
    Yan W; Shin KS; Wang SJ; Xiang H; Divers T; McDonough S; Bowman J; Rowlands A; Akey B; Mohamed H; Chang YF
    J Vet Sci; 2014; 15(2):249-58. PubMed ID: 24136208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.
    Negm OH; MacKenzie B; Hamed MR; Ahmad OAJ; Shone CC; Humphreys DP; Ravi Acharya K; Loscher CE; Marszalowska I; Lynch M; Wilcox MH; Monaghan TM
    Clin Exp Immunol; 2017 Jun; 188(3):437-443. PubMed ID: 28213939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection.
    Cook L; Wong MQ; Rees WD; Schick A; Lisko DJ; Lunken GR; Wang X; Peters H; Oliveira L; Lau T; Mah R; Bressler B; Levings MK; Steiner TS
    Inflamm Bowel Dis; 2024 May; 30(5):820-828. PubMed ID: 37874904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.